Exhibit 99.1 Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results ● Q4 2023 revenue of $7.3 million, representing a 109$31.6 million with product sales and royalty revenues of $26.1 million, a 132% increase from 2022 ● Announced successful results from ET-400’s pivotal bioequivalence study, NDA submission planned for Q2 2024 ● Management to hold co ...